Our latest developments
In2Innovation: Recycling of waste wood
At TNO, we are In2Innovation. In this series, you will meet the TNO employee behind the innovation. What do they do and what impact does their work have on society? Armed with a blue pop filter, Camilla van Wirdum takes us to all corners of the organisation. In this episode, we talk to Jan de Jong, Wood in Construction project leader, about how a CT scanner contributes to reuse of wood.
Favourable business case for solar heat in homes
Solar heat can make an important contribution to increasing the sustainability of our heat supply. Photovoltaic-thermic (PVT) systems on the roof can, in combination with a heat pump, supply homes with heat and hot water. This would make natural gas redundant, thereby decreasing carbon emissions. There are plenty of options, but what about the cost-benefit analysis?
TNO’s view of 2030: Getting a grip on climate change from space
Greenhouse gas emissions in the atmosphere are one of the main contributors to climate change and must therefore be rapidly reduced if we are to meet the 2030 climate targets. TNO is working on new satellite technology that makes it possible to do so. Because the better we identify emissions, the more targeted the action we can take.
TNO helps accelerate drug development through insight
To find the most effective interventions for complex metabolic diseases, we must first understand the dynamics of disease onset and progression. Only then can key targets and optimal therapeutic windows for more effective treatment be defined. We spoke with Anita van den Hoek, Research Scientist for TNO Metabolic Health, about how TNO helps pharmaceutical companies accelerate drug development through better understanding of disease pathways.
TNO proves method for effective pediatric drug development
Safe and effective drug dosing for young children come with their own challenges. Up to the age of 18, a child’s metabolism can change significantly. And in the first two years of life, those ontogenic differences can be rapid and dramatic. TNO published its findings from the first drug disposition (mass balance/metabolite profiling) study to conclusively prove that microtracing with accelerator mass spectrometry (AMS) is an effective way to collect clinical data in these young patients. This AMS technology can also be the key to building up more data on drug interventions in pregnant and lactating mothers.
Contact us
